Institutional Buyers Support Abbott After Better Than Expected Margins

DividendStocks.com Newsletter

Unsubscribe

One webinar worth putting on your calendar. (From Trade Thirsty)

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street

Written by Thomas Hughes on July 16, 2026 

Abbott logo displayed on a glass office building exterior at the company's headquarters.

Key Points

  • Abbott Laboratories posted solid Q2 results, with 13% reported growth and 4.8% organic growth, showing Exact Sciences integration is proceeding better than expected.
  • Adjusted EPS of $1.31 beat forecasts, and improved earnings guidance alongside limited margin contraction boosted investor sentiment and the share price.
  • Abbott maintains strong capital returns as a Dividend King with a 2.8% yield, supported by broad institutional buying and firming analyst price targets.
  • Special Report: He bet half his $9 billion on ONE stock (From Stansberry Research)

Abbott Laboratories (NYSE: ABT) gave the market what it wanted in its Q2 earnings report, affirming that the Exact Sciences acquisition was a good one. The critical takeaways are that comp growth is solid, the Exact Sciences business has traction, and the near-term margin impairment the acquisition brought is less than expected.

Looking forward, profitability metrics have improved, leading to improved guidance, strengthened market sentiment, and a robust rebound in the share price.

The share price rebound is an operative factor in the second half of 2026. Abbott’s market was overly depressed, given its historical value and capacity for capital returns, signaling a buying opportunity for investors.

The post-release surge not only confirms support at the existing lows but is also backed by MACD and stochastic signals, suggesting a full reversal is in play. The market completely misjudged the Exact Sciences deal, focusing too intently on near-term margin pressure and execution risk, rather than the long-term commercial impact on revenue, margins, and earnings.

ABT chart showing a bottom prior to the Q2 earnings release, with a 5% premarket surge after the release.

My top 3 AI picks for the next decade (Ad)

Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005.

Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.Click here to get all three AI stock names from Alexander Green

Abbott Laboratories Q2 Report a Balm for Frayed Investor Nerves

Abbott Laboratories’ Q2 report is solid, with reported growth of 13% and organic growth of 4.8%. Strength was underpinned by Exact Sciences and the 42.3% increase in Diagnostic services it brought, aided by an 8.4% increase in Established Pharmaceuticals and a 7.9% increase in Medical Devices. Nutrition, among the smaller segments, declined by 3.1%. Regionally, strengths were seen domestically and abroad.

Margin news was the catalyzing factor. The company’s margins contracted but less than expected, leaving gross margin, operating and net income above analysts’ forecasts. The critical takeaway is that $1.31 in adjusted earnings per share (EPS) outperformed by 235 basis points and is sufficient to sustain financial health while reinvesting and returning capital to shareholders.

Guidance is another catalyzing factor for back-half trading. The company maintained its forecast for organic revenue growth but improved the outlook for earnings, lifting the midpoint and narrowing the range for full-year results. With momentum building and results forecasted to accelerate in the back half, the guidance is likely to be cautious, setting the stage for additional catalysts by year’s end.

Abbott’s Capital Return Outlook Improves

Abbott’s capital return was never in any real danger, but the threat of margin compression and cash flow impairment was sufficient to weigh on sentiment. The takeaway from the Q2 release, however, is that concerns are misplaced. Capital returns will continue to flow, including the dividendand share buybacks, and buybacks may accelerate.

As it stands, Abbott is a Dividend King with nearly 55 consecutive increases to its credit, a manageable 70% payout ratio, and buybacks to offset the impact of annual increases and build shareholder leverage. The dividend yield is more than attractive, as of mid-July, at a historical high of approximately 2.8%, and Q2 buybacks reduced the count by 0.45%.

The $15 Gold Fund That Pays Up to $1,152/Month (Ad)

Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors – no mining stocks, no options, no physical metal required.

Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold’s rally into reliable monthly payouts. The next distribution is just days away.Discover the gold income fund before the next payout date

Analysts and Institutional Trends Reveal Optimistic Support for ABT Shares

Analysts’ trends reflect the dividend safety and deep value opportunity presented this year. While price targets have moderated, the market overreacted and moved below the low end of the target range. Price targets suggest a floor near $90, with potential for substantial upside at the consensus. Valuation metrics suggest the upside will run into the triple digits over time.

The likely outcome is that analysts’ price targets begin to firm, increasing conviction in the consensus and potential for a full stock price recovery. Until then, institutional activity suggests this group limits risk in 2026, owning more than 75% of the shares and buying on balance. Buying is broad-based, including funds, mutual funds, public retirement accounts, and private wealth managers.

Abbott’s risks center on legacy issues related to its baby formula business, competition in the MedTech sector, and the integration of Exact Sciences. Integration risks now appear limited, given the Q2 release and guidance update, leaving competition and legacy issues as the primary hurdles. Competition is being mitigated through pipeline investment, with numerous positive developments reported this quarter. Legacy issues relate to baby formula manufacturing processes, regulatory scrutiny, and the unresolved legal issues they bring.

This year’s catalysts include the successful integration of Exact Sciences, the revenue and margin boost from Cologuard, and the expansion of Medtech wearables. Libre Duo, the world’s first dual glucose/keytone monitoring system, received the EU’s CE Mark, enabling its sales throughout the region, while pipeline news includes advances in two critical cardiovascular devices. What the market gets wrong is that ABT isn’t just a legacy healthcare company and bond proxy but an innovative med-tech company expanding margins while investing in growth.

Read this article online ›

Recommended Stories

Did you find this article useful?

I liked this article.
I did not like this article.

Thank you for subscribing to DividendStocks.com’s daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.

If you need help with your subscription, please don’t hesitate to contact MarketBeat’s South Dakota based support team at contact@marketbeat.com.

If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.

Copyright 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place, Sixth Floor, Sioux Falls, SD 57103-7078. United States of America..

Featured Link: BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?(From Awesomely)

Unknown's avatar

Published by RJ Hamster

I was born on 6 August 1956 in San Francisco, California to Janet and (the late) Richard Hovis. I grew up in Santa Monica, California where I attended elementary, junior high school, and high school (graduating in 1974), in addition to involvement in sports and recreation (Little League +, the Boy’s Club ++). Further, it was in elementary school – St. Augustine’s By-the -Sea Parish School that I found, and made the choice to truly journey with God. I attended Arizona State University from 1974 to 1977 – seeking to become an architect, however, I was not accepted, and, as such, I graduated with a Liberal Arts degree. Upon graduation from Arizona State University, I attended Cal Poly San Luis Obispo and studied City and Regional Planning at the Master’s level. I successfully completed one (1) year in a two (2) year program – I did not complete the Master’s degree in City and Regional Planning – due to personal reasons. I returned to Santa Monica where I started (October 1979) my career as graphic designer with Exxon Company, USA. I spent five years with Exxon Company, USA. While working with Exxon Company, USA I was accepted into architectural school – Sci-Arc in Southern California, however, I did not attend preferring to stay with Exxon.. In 1982 I married Laura Flosi and in April 1983 we had our one and only child – Lauren Alain Hovis – a gift from God. We moved to Phoenix, Arizona in 1984 from Los Angeles, where I went to work as a graphic designer with Kitchell CEM (from 1985 -1987). From 1987 – 1995 I was an independent contractor, and a registered representative in mortgage finance, financial management, graphic design, and drafting. Further, I attended the University of Phoenix and successfully obtained a Master’s in Business Administration (MBA) in 1982. I was also a member of the Scottsdale Jaycees, where I became very involved in community events and projects. In 1994, I accepted a cartography position with the Defense Mapping Agency in Reston, Virginia. As such, I relocated from Phoenix to Reston. In 1998, I was accepted and worked as a Visual Information Officer with the Central Intelligence Agency. In 2002, I worked as a Support Officer until my retirement (due to a need for shoulder surgery) in September 2018. Away from my Federal Government service, I have been involved in various organizations and activities in Northern Virginia. In November of 2011, I married Rebecca Ouellette in Santa Monica, California. I reside in San Tan Valley, AZ with my two hamster - Jess and Timothy, our fish, our lizard - RJ Lizard., and our cats - Pearl and Grey. As to hobbies, I enjoy playing sports, attending sporting events, mentoring individuals from financial management to hamsters, building models, photography, travel, multimedia design, managing partner for RJ Hamster, and jazz – smooth jazz to a samba or a bossa nova. Love and God Bless, Peter – aka RJ Hamster Jo hi

Leave a Comment